The data demonstrate that TB202-3 and TB202-63 protected against weight loss, an indicator of disease severity, starting at 1 mg/kg in a hamster challenge model, and TB181-36 protected against weight loss at 5 mg/kg and 10 mg/kg, according to Twist. In comparison, control animals lost 12% of their body weight.

TB202-63 and TB202-3 are single-domain VHH (nanobody) candidates found through synthetic antibody discovery libraries for candidates that could bind to the SARS-CoV-2 S1 receptor. TB181-36 is an immunoglobulin G (IgG) antibody based on those found in individuals recovered from COVID-19.

The studies were conducted in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Vanderbilt University Medical Center. Twist plans to explore opportunities to further develop all three antibodies internally or with partners.

Firms partner with Microsoft to advance DNA data storage
Twist Bioscience, Illumina, and Western Digital have formed an alliance with Microsoft to advance the field of DNA data storage.

ImmunoPrecise, Twist collaborate on novel therapeutics
ImmunoPrecise subsidiary Talem Therapeutics and Twist Bioscience will collaborate on the creation of novel therapeutic molecules.

Twist Bioscience finds new SARS-CoV-2 neutralizers
Twist Bioscience has identified immunoglobulin G antibodies and single dose domain VHH nanobodies that have neutralizing effects against SARS-CoV-2.

Twist Bioscience, Seismic Bio partner to discover bispecific antibodies
Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.

Takeda, Twist partner on biologics discovery
Twist Bioscience and Takeda Pharmaceutical have formed a partnership for access to Twist's proprietary phage display libraries for the discovery of antibodies...